drugset / Trial / NCT02103647

Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation

NCT02103647

Phase 1 Completed 24 enrolled IlDong Pharmaceutical Co Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to immediate release capsule(150mg \* 2) while multiple dosing.

Timeline

Start
2013-05
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregabalin Small molecule 150 mg
Comparator Pregabalin Small molecule 300 mg
Subject sustained release tablet Unknown 300 mg

Indications

No indication recorded.